Pharmaceuticals News

Company announcement no. 25 - 2614 July 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as...

Nucleome Therapeutics strengthens global IP portfolio with US patent for MCC Technology, the central technology of Nucleome’s 3D genomics platform.

ViCentra appoints Ian Wells as CFO and MedTech leader Tom West to its Board, strengthening leadership as it scales across Europe and eyes the U.S.

PMN310 demonstrated dose-dependent reduction of amyloid-beta oligomers in human cerebrospinal fluid following a single dose in healthy volunteers Represents one of the first quantitative measures...

The new test enables clinicians to reliably diagnose HDV and monitor patients’ treatment response.Hepatitis D  affects nearly 12 million of people globally and  is considered the most aggressive form...

SAN DIEGO, July 13, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...

WARREN, N.J., July 13, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) announced that its 2026 Annual Meeting of Stockholders (the “Annual Meeting)” is...

NEW YORK, July 13, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has achieved...

LEQEMBI IQLIK is a first-of-its-kind anti-amyloid treatment worldwide, offering at-home dosing for initiation and maintenance (approved in the U.S.) U.S. launch of LEQEMBI IQLIK as an initiation dose...

NEW YORK and LONDON and LEAMINGTON, Ontario, July 13, 2026 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a global lifestyle and consumer packaged...